Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05319340
Other study ID # 678657
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 15, 2014
Est. completion date March 2, 2021

Study information

Verified date March 2021
Source I.M. Sechenov First Moscow State Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-institution uncontrolled open-label trial.


Description:

The single-institution uncontrolled open-label trial is to optimize the anticoagulant therapy in the out-patient practice. The study embraces patients who are advised to take the anticoagulant therapy for some reasons. The study has two phases - a retrospective part and a concurrent part. At the first phase, researchers analyze the compliance with the anticoagulant therapy in the real clinical practice. At the concurrent phase, researchers conduct a single-institution uncontrolled open-label trial to evaluate the effectiveness, safety of the anticoagulant therapy and compliance with it at the antithrombotic therapy control ward, and estimate the glomerular filtration rate in patients taking the anticoagulant therapy.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date March 2, 2021
Est. primary completion date March 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: - the age above 18 - indications for the anticoagulant therapy - informed consent for inclusion into trials Exclusion Criteria: - denial to proceed in the trial Non-inclusion criteria: pregnancy and lactation - Intracerebral hemorrhage within three preceding months - severe mental disorders* which could possibly affect the anticoagulant therapy dosage schedule - anemia and a decrease in Hb by ?100 GM/DL* - active gastroduodenal ulcer - active bleeding during the preceding month - other intensive bleeding instances as per the TIMI Score within three weeks before the inclusion - severe hepatic impairment for over 10 points under the Child-Pugh Score - oncology disease with the life expectancy less than one year

Study Design


Related Conditions & MeSH terms


Intervention

Other:
prescribing anticoagulant therapy
Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
I.M. Sechenov First Moscow State Medical University

References & Publications (1)

Chashkina MI, Kozlovskaya NL, Andreev DA, Ananicheva NA, Bykova AA, Salpagarova ZK, Syrkin AL. [Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments]. Kardiologiia. 2020 Mar 5;60(2):41-46. doi: 10.18087/cardio.2020.2.n823. Russian. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other minor bleeding Minor bleeding shall mean any visually observed bleeding, including that discovered with various imaging methods, which cause a decrease in HB by less than 30 GM/DL or Ht by less than 9%. in 1-2-3-6 years after the anticoagulant therapy is prescribed
Primary kidney compliance with the anticoagulant therapy and its safety and trends in the kidney function During a visit to the clinic, the patient will be surveyed and tested for the creatinine level Evaluation of GFR, bleeding and thrombotic complications after 2 years
Primary death due to any cause phone survey when patients are invited to the clinic in six years after the anticoagulant therapy is prescribed
Primary cardiovascular mortality Phone survey when patients are invited to the clinic. The term cardiovascular mortality means a set of fatal heart attacks, fatal strokes, sudden death, fatal thromboembolism. Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 2 years
Primary kidney function trend phone survey when patients are invited to the clinic for testing the creatinine level and further estimation of the glomerular filtration rate Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 3 years
Primary intensive bleeding phone survey when patients are invited to the clinic. Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 6 years
Secondary frequency of thromboembolic events patients will be surveyed upon their visit to the clinic. Thromboembolic events shall mean non-fatal embolic strokes, systemic embolism, acute coronary syndrome (to be corroborated with documents). in 1-2-3-6 years after the anticoagulant therapy is prescribed
See also
  Status Clinical Trial Phase
Terminated NCT02128841 - Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. Phase 2
Recruiting NCT03670446 - Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants:A Study on Behavioral Patterns N/A
Recruiting NCT03666962 - Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT01033279 - Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy N/A
Completed NCT00287313 - Daily Vitamin K in Patients on Warfarin With Unstable INRs N/A
Completed NCT00222638 - Influenza Vaccination and Oral Anticoagulant Therapy Phase 4
Active, not recruiting NCT06203795 - Dialysis Performance of the FX CorAL Membrane N/A
Completed NCT03864900 - Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence N/A
Active, not recruiting NCT06401863 - Shared Decision for Drug Interactions in Oral Anticoagulation N/A
Not yet recruiting NCT04977076 - Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention N/A
Recruiting NCT04861103 - Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH) Phase 4
Completed NCT01653405 - Improving Anticoagulation Control in VISN 1 N/A
Not yet recruiting NCT05820854 - Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
Completed NCT04681482 - Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
Not yet recruiting NCT06137794 - Application of "I-Anticoagulation"in Patients With Atrial Fibrillation N/A
Completed NCT02103101 - Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events N/A
Completed NCT05065502 - MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings N/A
Recruiting NCT03965208 - Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation Phase 4
Completed NCT03318393 - Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO Phase 4